Request Demo

Last update 09 Sep 2025

Telmisartan

Last update 09 Sep 2025

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

4'-[(1,4'-dimethyl-2'propyl[2,6'-bi-1H-benzimidazol]-1'-yl)methyl]-[1,1'-biphenyl]-2-carboxylic acid, 4'-[(1,7'-dimethyl-2'-propyl-1H,3'H-2,5'-bibenzimidazol-3'-yl)methyl]biphenyl-2-carboxylic acid, Telmisartan

+ [69]

Target

AT1R

Action

antagonists

Mechanism

AT1R antagonists(Angiotensin II Receptor Type 1 antagonists)

Therapeutic Areas

Cardiovascular Diseases

Active Indication

Cardiovascular DiseasesEssential HypertensionHypertension

Inactive Indication

Diabetes MellitusDiabetes Mellitus, Type 2Diabetic Nephropathies+ [6]

Originator Organization

Boehringer Ingelheim GmbH

Active Organization

Bayer AGBoehringer Ingelheim International GmbHTeva Pharmaceuticals Europe BV

+ [9]

Inactive Organization-

License Organization-

Drug Highest PhaseApproved

First Approval Date

United States (10 Nov 1998),

Hypertension

RegulationPriority Review (China)

Structure/Sequence

Molecular FormulaC33H30N4O2

InChIKeyRMMXLENWKUUMAY-UHFFFAOYSA-N

CAS Registry144701-48-4

347

Clinical Trials associated with Telmisartan

ChiCTR2500108026

Not ApplicableIIT

Efficacy and safety of Ambrisentan on idiopathic membranous nephropathy----a prospective, multi-center, randomized and controlled study

Start Date01 Sep 2025

Sponsor / Collaborator

The Second Military Medical University

[+1]

NCT06815497

/ Not yet recruitingPhase 2IIT

Phase II Non-Randomized, Unblinded, Single-Center Trial of Telmisartan in Combination With Cytotoxic Regimens in Platinum-Resistant Ovarian Cancer Versus Historical Best Supportive Care

The primary study objective is to assess progression-free survival in patients with ovarian cancer receiving telmisartan plus selected standard of care chemotherapy regimens versus historical controls.

Start Date14 Aug 2025

Sponsor / Collaborator

Dartmouth-Hitchcock Medical Center

[+1]

TCTR20241006001

/ RecruitingPhase 3

A Randomized, Double-blind, Multi-center, Active-controlled, Phase 3 clinical trial to Evaluate the Efficacy and Safety of Combination Therapy of THP-00101, THP-00102, and THP-00103 in Subjects with T2DM and Essential Hypertension

Start Date10 Apr 2025

Sponsor / Collaborator

THPharm

100 Clinical Results associated with Telmisartan

100 Translational Medicine associated with Telmisartan

100 Patents (Medical) associated with Telmisartan

4,301

Literatures (Medical) associated with Telmisartan

01 Dec 2025·JOURNAL OF PHOTOCHEMISTRY AND PHOTOBIOLOGY A-CHEMISTRY

Aquatic photochemistry and transformations of multiclass emerging organic contaminants in environmental water matrices

Author: Bajt, Oliver ; Prosen, Helena ; Kravos, Aleksander

This study shows a comprehensive assessment of the photodegradation of 18 multiclass contaminants of emerging concern (CECs) in simulated river and marine aquatic compartments.Degradation trends, mineralization, and defluorination of the target CECs were monitored in model matrixes, artificial and real seawater, with and without aeration.Each model matrix contained a natural abiotic factor of interest, i.e., chloride, nitrate, humic acid, lignosulfonate, and iron, all naturally present in surface water.Transformation pathways were investigated by UHPLC-MS/MS and for the identified transformation products (TPs), their ecotoxicities were predicted in silico.Only 8 out of 18 selected CECs were found to be significantly photolabile, especially rosuvastatin.Direct photolysis was their primary degradation route, while abiotic factors either accelerated or suppressed the degradation depending on the type of CEC.Real and artificial seawater mostly acted inhibitory.Oxygen aeration mostly accelerated degradation showing the effect of singlet oxygen.Low mineralization and defluorination were in most cases linked to the formation of stable and relatively more toxic TPs, which were characteristic for rosuvastatin.Main identified TPs were screened in real river water and seawater (North Adriatic Sea water basin, Slovenia, Europe).Rosuvastatin′s TP ROS-349 was detected with a high confidence level for the first time, which may raise environmental concerns.Overall, advanced assessment of aquatic photochem. is achieved by using low concentrations, mixtures of multiclass CECs, UV light above 300 nm, more realistic matrixes, as well as by identifying, ranking, and analyzing the TPs in actual aquatic environment.

01 Nov 2025·Current Vascular Pharmacology

Efficacy of Dapagliflozin and Telmisartan Combination Therapy in Reducing Albuminuria and Inflammatory Markers in Diabetic Nephropathy: A Prospective Observational Study

Article

Author: Bhandari, Uma ; Chauhan, Shalu ; Habib, Anwar

Background::

Diabetic nephropathy, a major contributor to chronic kidney disease, is closely associated with inflammatory responses.

Objective::

This study aimed to evaluate the effectiveness of combination therapy with dapagliflozin and telmisartan in treating diabetic nephropathy and its effect on patient’s albuminuria levels.

Material and Methods::

We conducted a 12-week prospective observational study to assess diabetic nephropathy. Patients with diabetic nephropathy were treated with either dapagliflozin and telmisartan (n=92) or telmisartan alone (n=92). Measurements of waist-to-hip ratio, fasting blood glucose, hemoglobin A1c (HbA1c), blood pressure, urinary albumin-to-creatinine ratio (UACR), estimated glomerular filtration rate (eGFR), uric acid, blood urea nitrogen, lipid profile, and inflammatory biomarkers, including C-C motif chemokine ligand 21 messenger RNA (CCL21 mRNA) and monocyte chemoattractant protein-1 (MCP-1), were obtained at baseline and following 12-weeks of treatment.

Results::

Dapagliflozin and telmisartan combination therapy demonstrated a significant decrease in UACR compared with baseline levels (p<0.001). After treatment, the dapagliflozin and telmisartan group had significantly lower waist-to-hip ratio, fasting blood glucose, HbA1c, uric acid, total cholesterol, and low-density lipoprotein compared with the monotherapy group (p<0.05). Additionally, inflammatory biomarkers, including CCL21 mRNA and MCP-1, were substantially lower in the combination therapy group than in the monotherapy group (p<0.05).

Conclusion::

In comparison to monotherapy, combination therapy demonstrated more significant clinical effects in treating diabetic nephropathy. This combination therapy effectively controls blood glucose levels and UACR, reduces inflammatory responses, and improves kidney function recovery in diabetic nephropathy patients, thereby enhancing the overall clinical treatment outcomes for these patients.

02 Sep 2025·INTERNATIONAL JOURNAL OF ENVIRONMENTAL ANALYTICAL CHEMISTRY

Development and application of a sustainable approach for the determination of 95 pharmaceutical substances and metabolites in urban wastewater by means of ultra-high-performance liquid-chromatography-tandem mass spectrometry

Author: Vincenti, Marco ; Gerace, Enrico ; Minella, Marco ; Privitera, Dana ; Salomone, Alberto ; Massano, Marta ; Alladio, Eugenio

In the last few years, the interest in pharmaceutical drugs and their metabolites as environmental pollutants is gaining growing importance.Regular monitoring and timely actions are decisive to implement appropriate water resource management strategies and to evaluate the efficiency of traditional or innovative wastewater treatment plants (WWTPs).This study describes the development and validation of an anal. procedure using 10 mL sample volume followed by direct-injection in ultra-high-performance liquid chromatog.-tandem mass spectrometry (UHPLC-MS/MS) for the simultaneous determination of 95 pharmaceutical drugs and 10 of their main metabolites in wastewater.Adequate sensitivity was recorded for all target analytes, with limits of detection below 5 ng/L for 60 out of 95 analytes and recoveries exceeding 80% for all the analytes under study.A total of 42 target analytes were detected in almost all sites, and limited differences were observed among several pharmaceutical drug arrays found at different sampling sites.In addition, an abatement yield higher than 50% was observed for only 12 of the 42 detected substances.The procedure, which combined direct injection and small sample volume collection, showed great potential and efficiency for the high-performance determination of pharmaceutical drugs in wastewater.

News (Medical) associated with Telmisartan

29 Aug 2025

·www.einpresswire.com

January - March 2021 | Potential Signals of Serious Risks/New Safety Information Identified by the FDA Adverse Event Reporting System (FAERS)

Addyi (flibanserin) Drug hypersensitivity The "Contraindications", "Warnings and Precautions", "Adverse Reactions", and "Medication Guide" sections of the labeling were updated in September 2021 to include hypersensitivity reactions. Addyi labeling Glucagon-like peptide-1 (GLP-1) analogues Adlyxin (lixisenatide) Bydureon (exenatide) Bydureon BCise (exenatide) Byetta (exenatide) Ozempic (semaglutide) Rybelsus (semaglutide) Saxenda (liraglutide) Soliqua (insulin glargine and lixisenatide) Trulicity (dulaglutide) Victoza (liraglutide) Xultophy (insulin degludec and liraglutide) Drug-induced liver injury The "Adverse Reactions" section of the liraglutide and dulaglutide labeling was updated in June 2022 to include information about elevations of liver enzymes. Example: Trulicity labeling FDA determined that no action is necessary at the time for lixisenatide, exenatide, and semaglutide based on available information. Alcohol-based hand sanitizers Exposure via inhalation FDA determined that no action is necessary at the time based on available information. A FDA Drug Safety Communication was issued on June 16, 2021. Amlodipine and Levamlodipine Products Azor (amlodipine and olmesartan medoxomil ) Caduet (amlodipine besylate and atorvastatin calcium) Conjupri (levamlodipine maleate) Consensi (amlodipine besylate and celecoxib) Exforge (amlodipine and valsartan) Exforge HCT (amlodipine/valsartan and hydrochlorothiazide) Lotrel (amlodipine besylate and benazepril hydrochloride) Katerzia (amlodipine benzoate) Norvasc (amlodipine besylate) Prestalia (amlodipine besylate and perindopril arginine) Tribenzor (amlodipine besylate/olmesartan medoxomil and hydrochlorothiazide) Twynsta (amlodipine and telmisartan) Non-cardiogenic pulmonary edema FDA determined that no action is necessary at the time based on available information. Avonex (interferon beta-1a) Betaseron (interferon beta-1b) Extavia (interferon beta-1b) Plegridy (pegylated interferon beta-1a) Rebif (interferon beta-1a) Injection site abscess FDA is evaluating the need for regulatory action. Bavencio (avelumab) Imfinzi (durvalumab) Keytruda (pembrolizumab) Libtayo (cemiplimab-rwlc) Opdivo (nivolumab) Tecentriq (atezolizumab) Scleroderma FDA determined that no action is necessary at the time based on available information. Bavencio (avelumab) Imfinzi (durvalumab) Keytruda (pembrolizumab) Libtayo (cemiplimab-rwlc) Opdivo (nivolumab) Tecentriq (atezolizumab) Cholangitis sclerosing The "Adverse Reactions" section of the Keytruda (pembrolizumab) labeling was updated in August 2021 to include sclerosing cholangitis. Example: Keytruda labeling FDA determined that no action is necessary at the time for Bavencio (avelumab), Imfinzi (durvalumab), Libtayo (cemiplimab-rwlc), Opdivo (nivolumab), and Tecentriq (atezolizumab) based on available information. Chloroquine Generic products containing chloroquine Phospholipidosis The “Warnings” section of the labeling was updated in May 2022 to include information about phospholipidosis. Eliquis (apixaban) Pradaxa (dabigatran etexilate mesylate) Savaysa (edoxaban tosylate) Xarelto (ribaroxaban) Generic products containing dabigatran etexilate mesylate Generic products containing ribaroxaban Menorrhagia The “Use in Specific Populations” section was updated April 2021 to add language to describe the risk of clinically significant uterine bleeding in females of reproductive potential. Eliquis label Pradaxa label Savaysa label Xarelto label Depakote (divalproex sodium) Depakote ER (divalproex sodium) Stavzor (valproic acid) Generic products containing divalproex sodium Generic products containing valproic acid Tubulointerstitial nephritis The "Adverse Reactions" section of the labeling was updated in November 2021 to include tubulointerstitial nephritis. Example: Depakote labeling Dupixent (dupilumab) Alopecias FDA is evaluating the need for regulatory action. H.P. Acthar Gel (corticotropin) Anaphylactic and anaphylactoid responses The "Warnings and Precautions" and "Adverse Reactions" sections of the labeling were updated in October 2021 to include anaphylaxis. Acthar Gel labeling H.P. Acthar Gel (corticotropin) Cardiac arrhythmias The "Warnings and Precautions" and "Adverse Reactions" sections of the labeling were updated in October 2021 to include atrial fibrillations and palpitations. Acthar Gel labeling Ibrance (palbociclib) Kisqali (ribociclib) Kisqali Femara Co-Pack (letrozole and ribociclib) Verzenio (abemaciclib) Second primary malignancy FDA determined that no action is necessary at the time based on available information. Lynparza (olaparib) Drug-induced liver injury FDA determined that no action is necessary at the time based on available information. Ocrevus (ocrelizumab) Autoimmune colitis The "Warnings and Precautions", "Adverse Reactions", "Patient Counseling Information", and "Medication Guide" sections of the labeling were updated in August 2022 to include colitis. Ocrevus labeling Poteligeo (mogamulizumab-kpkc) Acute kidney injury The "Warnings and Precautions" section of the labeling was updated in March 2022 to include glomerulonephritis. Poteligeo labeling Ravicti (glycerol phenylbutyrate) Product labeling issue regarding stability and instructions for administration The container label, carton label, "Medication Guide", and sections of the Prescribing Information ("Dosage and Administration" and "Patient Counseling Information") were updated in September 2021 to enhance the instructions for administration. Ravicti labeling Spravato (esketamine) Hypertensive crisis FDA determined that no action is necessary at the time based on available information. Tremfya (guselkumab) Device use errors resulting in possible missed or partial doses The Tremfya One Press Instructions for Use (IFU) and carton labeling was updated in June 2023 to mitigate medication errors, such as underdose or no dose delivered. Tremfya labeling Trulance (plecanatide) Drug hypersensitivity The “Adverse Reactions” section of the Trulance labeling was updated April 2021 to include skin itching, hives, and rash. Trulance Label Trulance (plecanatide) Vomiting The “Adverse Reactions” section of the Trulance labeling was updated April 2021 to include vomiting. Trulance Label Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Drug Approval

21 Jul 2025

·www.globenewswire.com

George Medicines signs exclusive licensing agreement with Azurity Pharmaceuticals to commercialize WIDAPLIK™ (telmisartan, amlodipine and indapamide) tablets in the US

George Medicines signs exclusive licensing agreement with Azurity Pharmaceuticals to commercialize WIDAPLIK™ (telmisartan, amlodipine and indapamide) tablets in the US An innovative single pill combination of three medicines, including two doses that are lower than those currently available in single pill combinations, that can deliver the blood pressure-lowering benefits of a triple combination therapy early in the treatment pathway, as demonstrated in clinical trials, with an established safety profile Azurity gains exclusive US rights to commercialize the first and only FDA-approved triple combination medication for the treatment of hypertension, including as initial treatment, to lower blood pressureUS commercialization anticipated in Q4 2025 London, UK, Boston, MA, USA, 21 July 2025 – George Medicines, a late-stage biopharmaceutical company focused on addressing significant unmet needs in cardiometabolic disease, has entered into an exclusive licensing and supply agreement with Azurity Pharmaceuticals (“Azurity”), a privately held global pharmaceutical company committed to delivering innovative, high-quality medicines for overlooked patients, granting Azurity exclusive rights to commercialize WIDAPLIK in the United States. WIDAPLIK is indicated for the treatment of hypertension, including as initial treatment, to lower blood pressure. It is a proprietary single pill combination of three medicines: telmisartan, amlodipine and indapamide and is available in three doses (10/1.25/0.625 mg, 20/2.5/1.25 mg, and 40/5/2.5 mg strengths), including two doses that are lower than those currently available in single pill combinations. It is the first and only FDA-approved triple combination medication for use as an initial therapy in patients likely to need multiple drugs to achieve blood pressure goals. WIDAPLIK, with its three different doses, can deliver the efficacy benefits of a triple mechanism approach early in the treatment pathway with an established safety profile. WIDAPLIK carries a Boxed Warning for fetal toxicity and should be discontinued as soon as pregnancy is detected. Please see full Prescribing Information and Important Safety Information, including Boxed Warning for WIDAPLIK here.Azurity is granted a license to exclusively commercialize WIDAPLIK, supplied by George Medicines, in the U.S. in return for milestone and royalty payments. Citibank acted as transaction advisor to George Medicines. Azurity’s commercialization of WIDAPLIK is expected to commence in Q4 2025. Mark Mallon, Chief Executive Officer of George Medicines, said: “This second major licensing and supply agreement, following the agreement established with Bausch Health in January 2025, further signals the substantial momentum for this triple combination therapy and our commitment to bring this medicine to patients in need around the world. Hypertension remains one of the most persistent public health challenges in the United States, with only one in four adults with the condition having their blood pressure under control. Our agreement with Azurity marks a pivotal step in George Medicines’ commitment to address the unmet needs in hypertension management and improve outcomes for patients across the United States of America.” Ronald Scarboro, CEO, Azurity Pharmaceuticals, said: “This collaboration supports Azurity's commitment to bringing highly differentiated products to patients with unmet needs. WIDAPLIK is a novel fixed-dose combination designed to simplify hypertension management for patients likely to require multiple therapies. It is a great fit for our cardiovascular portfolio and unique commercialization capabilities. We are pleased to bring this newly approved treatment option to patients in the US.”About George Medicines George Medicines is a late-stage biopharmaceutical company addressing significant unmet need in the treatment of cardiometabolic diseases with innovative single-pill combinations of existing treatments, designed for a balance of efficacy and safety, with the potential to improve patient adherence. Multi-mechanism, single-pill combinations offer the potential to bring significant improvements in clinical outcomes with cardiometabolic disorders, including hypertension, which remain among the leading causes of premature death and disability worldwide. George Medicines is an independent spin-out company from The George Institute for Global Health, one of the world’s leading medical research institutes with a focus on addressing global health inequity. The Company is backed by George Health, the commercial arm of The George Institute, and Brandon Capital, Australia’s leading life sciences venture capital firm. For more information, please visit www.george-medicines.com. About Azurity PharmaceuticalsAzurity Pharmaceuticals is a privately held company committed to delivering innovative, high-quality medicines for overlooked patients. Azurity’s global footprint is over 50 countries, with a diversified portfolio of 50+ medicines spanning 10 dosage forms and 10 key therapeutic areas. Powered by its Next-Gen Commercial Model, Azurity leverages data, analytics, and AI-driven digital tools to enhance market reach and stakeholder engagement. Our medicines have benefited millions of people. For more information, please visit www.azurity.com. Disclosure notice: Azurity and George Medicines undertake no obligation to update or revise any forward-looking statements contained in this release as a result of new information, future events, or evolving circumstances. Media contacts ICR Healthcare David Daley, Lindsey Neville, Tom Daniel georgemedicines@icrhealthcare.com; Tel: +44 (0) 203 709 5700 Azurity Pharmaceuticals Media Relationsmedia@azurity.com © 2025 George Medicines Pty LimitedALL RIGHTS RESERVED.

License out/inDrug Approval

19 Jul 2025

·pharma.economictimes.indiatimes.com

185 drugs fail CDSCO quality Test; 4 samples flagged as Spurious

New Delhi: India’s drug regulator, the Central Drugs Standard Control Organization (CDSCO), identified 185 drug samples as ‘ Not of Standard Quality ’ (NSQ) and flagged four others as ‘spurious’ during its monthly quality review for June. Of the total NSQ samples, 55 were flagged by Central Drugs Laboratories , while the remaining 130 were reported by State Drugs Testing Laboratories. In addition, the CDSCO drug alert identified four spurious drug samples, including a Cefixime Tablet from Bihar, an ointment of Heparin Sodium and Benzyl Nicotinate from Delhi, and two samples of Rosuvastatin and Fenofibrate Tablets — Rosuvas F 10 and Rosuvas F 20—collected from Telangana. A drug is deemed spurious if it qualifies certain conditions detailed under Section 17-B of the Drugs and Cosmetics Act, 1940. Of the 55 samples flagged as NSQ by central testing laboratories includes Dextrose Injection manufactured by Tam-Bran Pharmaceuticals; Azithromycin Tablet by Apple Formulations; Paracetamol Intravenous Infusion by D.J. Laboratories Telmisartan Tablets by Healers Lab and 51 other samples. The 130 samples flagged by state laboratories includes several common medicines and supplements such as Paracetamol, Pantoprazole, Calcium , Vitamin D3 tablets and several other common drugs. The identification of drug samples as NSQ is done based on failure of the drug sample in one or the other specified quality parameters and the term NSQ has been defined under Section 16(1)(a) of the Drugs and Cosmetics Act, 1940. However, according to the Health Ministry, “identification of drug samples as 'NSQ' does not warrant any concerns on the other drug products available in the market. The CDSCO routinely notifies ‘'NSQ ' and spurious medicines based on a monthly review undertaken by the central and state drug regulatory bodies to ensure that these drugs are removed from the market and enforce quality norms. By Abhijeet Singh ,

100 Deals associated with Telmisartan

External Link

KEGG	Wiki	ATC	Drug Bank
D00627	Telmisartan	C09CA07	DB00966

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Cardiovascular Diseases	European Union	Actavis Group PTC ehf	29 Sep 2010
Cardiovascular Diseases	Iceland	Actavis Group PTC ehf	29 Sep 2010
Cardiovascular Diseases	Liechtenstein	Actavis Group PTC ehf	29 Sep 2010
Cardiovascular Diseases	Norway	Actavis Group PTC ehf	29 Sep 2010
Essential Hypertension	European Union	Bayer AG	11 Dec 1998
Essential Hypertension	Iceland	Bayer AG	11 Dec 1998
Essential Hypertension	Liechtenstein	Bayer AG	11 Dec 1998
Essential Hypertension	Norway	Bayer AG	11 Dec 1998
Hypertension	United States	Boehringer Ingelheim GmbH	10 Nov 1998

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Hypertriglyceridemia	Phase 3	Germany	Bayer AG	01 Nov 2007
Metabolic Syndrome	Phase 3	Germany	Bayer AG	01 Nov 2007
Hypercholesterolemia	Phase 3	United States	Boehringer Ingelheim GmbH	01 Apr 2006
Hypercholesterolemia	Phase 3	Czechia	Boehringer Ingelheim GmbH	01 Apr 2006
Hypercholesterolemia	Phase 3	France	Boehringer Ingelheim GmbH	01 Apr 2006
Hypercholesterolemia	Phase 3	Germany	Boehringer Ingelheim GmbH	01 Apr 2006
Hypercholesterolemia	Phase 3	Hong Kong	Boehringer Ingelheim GmbH	01 Apr 2006
Hypercholesterolemia	Phase 3	Netherlands	Boehringer Ingelheim GmbH	01 Apr 2006
Hypercholesterolemia	Phase 3	Russia	Boehringer Ingelheim GmbH	01 Apr 2006
Hypercholesterolemia	Phase 3	Slovakia	Boehringer Ingelheim GmbH	01 Apr 2006

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02373163 (INTERVENCION Trial \| INTERVENCION, CTgov)	Phase 4	Hypertension	166	Hydrochlorothiazide (Diuretic)	kzaytzysqa(yoiqkbrlys) = vnciikjcrs dpexdwqjef (xralipwlzt, 8.4) View more	-	29 Jul 2025
				Amlodipine (Calcium-channel Blocker)	kzaytzysqa(yoiqkbrlys) = mxslcubvur dpexdwqjef (xralipwlzt, 9.2) View more
NCT04518293 (GMRx2, Pubmed \| Lancet)	Phase 3	Hypertension	1,385	GMRx2 (telmisartan 20 mg, amlodipine 2·5 mg, and indapamide 1·25 mg)	slyecjhfvi(ywnmanzrwk) = aqxsyxpwdx asoylikyvs (dbsxgkreal )	Positive	01 Oct 2024
NCT02471833 (HEART, CTgov)	Phase 1/2	Alzheimer Disease	61	Telmisartan 20mg (Telmisartan 20mg)	bgcsejgjwj(ujelyezgar) = ralqbbiuca cvahctldds (wbusyreddm, 1425.34) View more	-	23 May 2024
				Telmisartan 40mg (Telmisartan 40mg)	bgcsejgjwj(ujelyezgar) = haqxepxlvo cvahctldds (wbusyreddm, 1509.02) View more
NCT02338232 (CTgov)	Not Applicable	Acute Graft Versus Host Disease	32	Telmisartan	dzshasrgxr = glexyykafq rkclulmctt (dpgpdffqiz, sbkpevsrny - gbuxlwidya) View more	-	01 May 2024
NCT04360551 (CTgov)	Phase 2	COVID-19 \| Complication	24	Telmisartan 40mg (Telmisartan)	sjspgxpsoy(kbgyckjwht) = urwhhpzulg mqquxolrhn (rvibgrtuke, xkdbmlcxxr - vwlsnxgnqt) View more	-	21 Aug 2023
				Placebo (Placebo)	sjspgxpsoy(kbgyckjwht) = qcifkquder mqquxolrhn (rvibgrtuke, gxiuvpeqdn - qcgbnrsksc) View more
NCT04736329 (TRIUMF trial, Pubmed \| Egypt Heart J)	Not Applicable	Heart failure with reduced ejection fraction	107	Telmisartan	nvjgcfoplw(gpwmpfqkid) = gglcxrqlhd lkobrhkkvg (fxwrbhtweo ) View more	Positive	08 Aug 2023
				Enalapril	nvjgcfoplw(gpwmpfqkid) = crbadwdjdh lkobrhkkvg (fxwrbhtweo ) View more
NCT04736329 (TRIUMF trial, ESC2023)	Not Applicable	Heart failure with reduced ejection fraction	107	Telmisartan	acssyqibag(qlqqclddag) = zmyfpfdbsp knavcujdme (jxpkirxipo ) View more	-	20 May 2023
				Enalapril	acssyqibag(qlqqclddag) = xqfkdxapyg knavcujdme (jxpkirxipo ) View more
NCT02593110 (TELEX, CTgov)	Not Applicable	Peripheral Arterial Disease	114	Supervised Treadmill Exercise Therapy+Telmisartan (Telmisartan + Supervised Treadmill Exercise Therapy)	njeoeygriu(ziwimbbjkb) = fsdfcoehuq lsyzfhjxfc (xwpihowzvl, 67.21) View more	-	11 Jan 2023
				"No exercise" control group+Telmisartan (Telmisartan + "No Exercise" Control Group)	njeoeygriu(ziwimbbjkb) = ttsxxroobd lsyzfhjxfc (xwpihowzvl, 47.33) View more
NCT02593110 (Pubmed \| JAMA)	Not Applicable	Peripheral Arterial Disease	114	Telmisartan plus exercise	kkqvhhqled(jpwagopbtm) = rwgawquyss ecdwwfunzc (ianmeuklzo )	Negative	04 Oct 2022
				Placebo plus exercise	kkqvhhqled(jpwagopbtm) = qtecybztms ecdwwfunzc (ianmeuklzo )
NCT03868839 (CTgov)	Phase 2	Schizoaffective disorder \| Schizophrenia, Treatment-Resistant	6	Telmisartan Pill	wkhhqhgyhu(hsqgswmvfx) = jendeacymz rfttjazgtr (chfwfgdcvz, 0.2377) View more	-	02 Mar 2022

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis